GlassScriptPhysician profile
Shoshana Eisenstein
NPI 1861620973
$5,576.18
in general payments reported to CMS, 2019-2025
32 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,224 · 2022: $1,044 · 2023: $1,181 · 2024: $1,112 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,077 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.51 |
| Education | $231.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $940.90 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $800.06 | 2021-2025 | |
| Astellas Pharma US INC | $512.03 | 2021-2024 | Veozah, Myrbetriq |
| Corcept Therapeutics | $500.42 | 2021-2025 | Korlym |
| Amgen INC. | $429.89 | 2021-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $396.14 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $302.30 | 2021-2025 | Zepbound, Mounjaro, Reyvow |
| Glaxosmithkline, LLC. | $250.56 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $148.38 | 2021-2022 | |
| Abbott Laboratories | $140.97 | 2024-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $123.58 | 2024-2025 | Gemtesa |
| Pfizer INC. | $114.62 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $83.30 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $81.35 | 2021-2022 | |
| Exact Sciences Corporation | $72.72 | 2025 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $71.89 | 2022 | |
| Eisai INC. | $69.69 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $68.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $63.74 | 2021-2022 | |
| Acella Pharmaceuticals, LLC | $50.87 | 2025 | NP Thyroid 60 |
| Tolmar, INC. | $48.43 | 2023-2025 | Eligard, Jatenzo |
| Genzyme Corporation | $42.89 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $40.83 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.81 | 2022 | |
| Antares Pharma, INC. | $33.94 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $32.88 | 2022-2023 | Livalo, Seglentis |
| Esperion Therapeutics, INC. | $27.35 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $20.77 | 2024 | Lumryz |
| E.R. Squibb & Sons, L.L.C. | $20.70 | 2022 | |
| Dexcom, INC. | $20.47 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $13.72 | 2025 | |
| Sanofi-Aventis U.S. LLC | $12.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shoshana Eisenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.